Osaka, Japan

Hiroyuki Ishitobi

This inventor holds 3 USPTO granted patents. Top assignee: Shionogi Company Limited. Active years: 1986-1992.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1986-1992

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hiroyuki Ishitobi: Innovator in Antibacterial Compounds

Introduction

Hiroyuki Ishitobi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of antibacterial research, holding a total of three patents. His work focuses on innovative compounds that aim to combat bacterial infections effectively.

Latest Patents

Ishitobi's latest patents include groundbreaking developments in the area of antibacterial agents. One of his notable inventions is the Piperaziniocephalosporins, which are antibacterial hydroxyarylpiperazinocephalosporins. These compounds are characterized by a specific formula that includes various substituents, allowing for effective bacterial treatment. Another significant patent involves alkylcarbamoyloxymethylcephem compounds, which are represented by a unique formula and are designed to serve as antibacterial agents.

Career Highlights

Hiroyuki Ishitobi has built a successful career at Shionogi & Company Limited, where he has been instrumental in advancing antibacterial research. His innovative approach and dedication to developing new compounds have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Throughout his career, Ishitobi has collaborated with esteemed colleagues, including Teruji Tsuji and Hiroshi Onoue. These partnerships have fostered a collaborative environment that enhances the research and development of new antibacterial solutions.

Conclusion

Hiroyuki Ishitobi's contributions to antibacterial research through his patents and collaborations highlight his importance in the field. His innovative work continues to pave the way for new treatments against bacterial infections.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…